We demonstrate by unsupervised hierarchical clustering of seven proteins that ER+/HER2– breast cancer patients with a tumour containing preferentially activated PI3K/MAPK pathways derived no benefit from adjuvant tamoxifen, while those without preferential activation had an improved RFI on tamoxifen. This evidence concerns the gene PIK3CA and neoplasm.